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S U M M A R Y
Objectives: In the performance of interferon gamma release assays (IGRA) for the diagnosis of
tuberculosis (TB) infection, false-negative results are a major obstacle. In active TB patients, treatment-
dependent changes of the negative test results remain unknown.
Methods: The treatment course of 19 smear-positive/culture-conﬁrmed TB patients who had IGRA-
negative results by QuantiFERON-TB in-tube (QFT-IT) method at the time of diagnosis (month 0) in a
previous study, were monitored in the present study. Blood was further collected at months 2 and 7, and
the concentrations of 27 immune molecules were measured in the plasma supernatants remaining after
performing the IGRA, using a suspension array system.
Results: After initiating treatment, eight of the 19 QFT-IT-negative patients showed positive conversion,
whereas the remaining 11 (58%) did not; the interferon gamma (IFN-g) response was restored to levels
higher than 1 IU/ml in only three of the eight patients with positive conversion. Plasma concentrations of
interleukin 1 receptor antagonist, interleukin 2, and interferon gamma-induced protein 10 remained low
after Mycobacterium tuberculosis-speciﬁc antigen stimulation at months 2 and 7 in the continuously QFT-
IT-negative group, whereas the parameters were elevated only in the transiently QFT-IT-negative group.
Conclusions: It was demonstrated that a majority of active TB patients showing negative IGRA results did
not regain sufﬁcient levels of immune responsiveness despite successful treatment.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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The interferon gamma release assay (IGRA) is currently used as
one of the representative tests to diagnose tuberculosis (TB)* Corresponding author. Tel.: +81 42 493 5711; fax: +81 42 492 4600.
E-mail address: nkeicho-tky@umin.ac.jp (N. Keicho).
http://dx.doi.org/10.1016/j.ijid.2015.09.021
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).infection.1 In this test, the cellular response to Mycobacterium
tuberculosis is assessed by measuring the interferon gamma (IFN-
g) released from peripheral blood lymphocytes after stimulation
with M. tuberculosis-speciﬁc antigens.1
The QuantiFERON-TB Gold In-Tube test (QFT-IT) is a commer-
cially available IGRA based on the ELISA method; it has a sensitivity
of 78–83% and speciﬁcity of 98–100%.1 This imperfect sensitivity
causes difﬁculties in ruling out TB infection, particularly when theciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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value of the test may reduce the chance of a possible therapeutic
intervention.
To assess the sensitivity of the QFT-IT, patients with bacterio-
logically proven active TB disease have often been recruited as
surrogates for individuals with latent TB infection. The IGRA results
also provide a clue to suspect active TB disease clinically.
Although weakened immunity in severe TB may affect the test
results,2 treatment-dependent changes of the negative IGRA
results with a very low IFN-g response have not been investigated
fully.
This study group has recently reported the results of a cross-
sectional study on the sensitivity of the QFT-IT method in Hanoi,
Vietnam, and demonstrated that aging, emaciation, HIV co-
infection, and a particular HLA genotype, DRB1*07:01, lowered
the sensitivity of the test in active pulmonary TB patients.3 In the
present study, 19 of the 24 patients who showed false-negative
results at the time of diagnosis were monitored. Further analysis of
the treatment response and dynamics of immune parameters was
performed, with the measurement of the concentrations of various
cytokines and chemokines in the plasma supernatants remaining
after use in the IGRA assay.
2. Methods
2.1. Study subjects and IGRA
From July 2007 to March 2009, whole blood was collected
from 504 adult patients in Hanoi, Vietnam, who had smear-
positive/culture-conﬁrmed pulmonary TB and a history negative
for TB treatment. The blood was collected in heparinized tubes
before anti-TB treatment was initiated (month 0).3 The patients
were tested with a commercially available ELISA-based IGRA
(QFT-IT; Cellestis, Victoria, Australia), as reported previously.3
Plasma supernatants were separated at 4000 rpm for 15 min
(Model 2010; Kubota Co., Tokyo, Japan) and stored at 80 8C
until measurement. The cut-off value to interpret the QFT-IT
results was set at 0.35 IU/ml, as per the manufacturer’s
instructions.
In the present study, further blood samples for QFT-IT and other
tests were collected and served for analysis at two more time
points: after the initial phase of treatment (month 2) and close to
the end of treatment (month 7). Positive conversion of the IGRA
was deﬁned by a negative result at month 0 and positive result(s)
at month 2, month 7, or both time points.
2.2. Clinical data collection
The extents of cavitary lesions and inﬁltrates were also semi-
quantitated by the grading method.4 M. tuberculosis isolates were
analyzed by single nucleotide polymorphism (SNP) and spoligo-
typing methods.5
2.3. Treatment course
Following the national standard regimen at that time, all
patients received an 8-month course of the anti-TB treatment
regimen 2S(E)HRZ/6HE, which was commonly administered
during the study period in Vietnam.5
2.4. Immune analyte proﬁling by Bio-Plex assay and adiponectin
ELISA assay
Immune molecules released into the plasma after TB antigen
stimulation were estimated from their concentrations after a 16- to
24-h incubation with TB-speciﬁc antigens (TBAg) minus those withno antigens (Nil) obtained from the QFT-IT method. Their
concentrations were determined using a human 27-plex assay
(14 cytokines: interleukin (IL)-1b, IL-1 receptor antagonist
(IL-1RA), IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12, IL-13, IL-15,
IL-17, IFN-g, tumor necrosis factor alpha (TNF-a); seven chemo-
kines: eotaxin, IL-8, IFN-g-inducible protein 10 (IP-10), monocyte
chemoattractant protein 1 (MCP-1), macrophage inﬂammatory
proteins MIP-1a and MIP-1b, RANTES; and six growth factors:
IL-7, ﬁbroblast growth factor (FGF) basic, granulocyte colony-
stimulating factor (G-CSF), granulocyte–macrophage colony stim-
ulating factor (GM-CSF), platelet-derived growth factor (PDGF)-BB,
vascular endothelial growth factor VEGF) (Bio-Plex Suspension
Array System; Bio-Rad, Hercules, CA, USA), following the
manufacturer’s instructions. All samples, standards, and controls
were run in duplicate and manipulated in accordance with the
manufacturer’s protocol. Samples were diluted in a 1:4 volume
ratio with the sample diluent and incubated for 30 min at room
temperature; they were then agitated at 300 rpm to be captured
with antibody-coupled magnetic beads. Following three washes in
a Bio-Plex Pro Wash Station, the samples were incubated with
biotinylated detection antibodies and agitated at 300 rpm in the
dark for 30 min at room temperature. Each captured analyte was
detected by the addition of streptavidin–phycoerythrin and
quantiﬁed using a Bio-Plex array reader. The ﬂuorescence
intensities in the samples and known standards were acquired
and converted to the plasma concentrations of each analyte using
the Bio-Plex 200 System software (version 6.0; Bio-Rad Laborato-
ries). When the induction of immune molecules after TB antigen
stimulation was below their detection limits, these molecules were
excluded from subsequent analysis.
Total human adiponectin (low, middle, and high molecular
weight) levels in plasma were also measured using the Quantikine
Human Total Adiponectin/Acrp30 Immunoassay Kit (R&D Systems,
Inc., Minneapolis, MN, USA). The mean minimum detectable dose
was 0.246 ng/ml.
2.5. Statistical analysis
Values including cytokine concentrations among groups were
analyzed by Kruskal–Wallis tests with multiple comparisons for all
pairs by Steel–Dwass method. The inequality of proportions
among the groups was analyzed by Fisher’s exact test. The
statistical analysis was performed using Stata version 12 (Stata
Corp, College Station, TX, USA) and JMP 9 (SAS Institute Inc., Cary,
NC, USA). A p-value of < 0.05 was considered to be statistically
signiﬁcant. The Bonferroni correction was also used for multiple
comparisons, when appropriate.
3. Results
3.1. Characteristics of the patients who completed the three-time
blood collection stratiﬁed by IGRA-negative or positive result at month
0
After the cross-sectional study reported previously,3 19 of the
24 IGRA-negative patients with culture-conﬁrmed active pulmo-
nary TB at the time of diagnosis completed the three-time blood
collection at months 0, 2, and 7; these patients were thus analyzed
in the present study. The 351 patients who initially showed QFT-
IT-positive results and completed the three-time blood collection
were set as a reference. Samples showing indeterminate results
before treatment were omitted from this analysis.
As expected from the results of the previous report,3 increasing
age, low body mass index (BMI) at the time of diagnosis, and the
HLA-DRB1*07:01 allele were observed more frequently in the
19 QFT-IT-negative patients than in the 351 QFT-IT-positive
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Resource 1). HIV co-infection was nearly signiﬁcantly associated
with QFT-IT-negative results (p = 0.0541). In addition, it was
possible to combine QFT-IT results with M. tuberculosis strain
genotypes in 90% of these patients. Approximately 60% of the M.
tuberculosis strains were of the Beijing genotype in this population,
according to the previous results of SNP analysis and spoligotyp-
ing.5 Non-Beijing strains, particularly EAI strains, were predomi-
nant in the QFT-IT-negative group as compared to the QFT-IT-
positive group (52.9% vs. 18.3%; p = 0.0004; Supplementary
Material, Online Resource 1).
3.2. Treatment course of the patients stratiﬁed by IGRA-negative or
positive result at month 0
During treatment, QFT-IT IFN-g values (TBAg minus Nil) of the
19 patients who showed QFT-IT-negative results at month
0 remained relatively low (Table 1).
The number of patients with a positive sputum smear was
relatively small at month 7, indicating that a majority of
the patients in both groups had been treated successfully; only
one of 19 (5.3%) and ﬁve of 351 (1.4%) patients were regarded
as treatment failure in the QFT-IT-negative and positive
groups, respectively, at month 0, and this difference was not
signiﬁcant (data not shown). The extent of cavitary lesions and
inﬁltrates on chest X-ray at month 0 and month 7 were also not
different between the QFT-IT-negative and positive groups
(Table 1).Table 1
Treatment response of the patients stratiﬁed by QFT-IT-negative or positive result at m
QFT-IT-positive result Month 0 
Month 2 
Month 7 
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Month 2 
Month 7 






























a n = 18 and n = 337 at month 0; n = 11 and n = 255 at month 7.
b n = 18 and n = 339 at month 0; n = 11 and n = 254 at month 7.3.3. Characteristics of the IGRA-negative patients at month 0 stratiﬁed
by the absence or presence of positive conversion during treatment
Eight of the 19 QFT-IT-negative patients showed positive
conversion at month 2 or month 7, whereas the remaining 11 (58%)
did not. Background information, such as age and low BMI, was
further compared between these two subgroups, but no particular
characteristics were statistically signiﬁcant (Table 2). Only three of
the eight patients with positive conversion showed IFN-g values
higher than 1 IU/ml at month 2 (1.0, 2.2, and 3.2 IU/ml) and month
7 (1.8, 5.2, and 10.0 IU/ml). These patients did not carry any of the
DRB1*07:01 alleles (data not shown), whereas all of the patients
carrying the HLA-DRB1*07:01 allele in the QFT-IT-negative group
showed IFN-g values lower than 1.0 IU/ml throughout the
treatment period (data not shown).
During treatment, sputum smear and chest X-ray ﬁndings were
not signiﬁcantly different between the subgroups with and
without positive conversion. A trace of cavitary lesions was not
observed in any of the ﬁve patients without positive conversion,
but was observed in three of the six patients with positive
conversion (Supplementary Material, Online Resource 2), al-
though this difference was not statistically signiﬁcant (p = 0.18).
3.4. Treatment-dependent changes in immunological parameters in
the blood from patients with IGRA-negative results before treatment
The concentrations of immune molecules induced by M.
tuberculosis antigen-speciﬁc antigens were analyzed in patientsonth 0
Negative result before
treatment (n = 19)
Positive result before
treatment (n = 351)
p-Value
0 (0.0%) 351 (100.0%) <0.0001
5 (26.3%) 312 (88.9%) <0.0001
6 (31.6%) 300 (85.5%) <0.0001
0.21 (0.05–0.25) 8.61 (3.46–14.9) <0.0001
0.11 (0.03–0.52) 3.80 (1.15–11.64) <0.0001
0.19 (0.02–0.79) 2.85 (0.88–8.82) <0.0001
19 (100.0%) 351 (100.0%) 1.0000
4 (21.1%) 40 (11.4%) 0.2623
1 (5.3%) 6 (1.7%) 0.3107
1 (5.3%) 5 (1.4%) 0.3107
0.6753
5 (27.8%) 105 (31.2%)
9 (50.0%) 174 (51.6%)
3 (16.7%) 46 (13.7%)
1 (5.6%) 8 (2.4%)
0 (0.0%) 4 (1.2%)
0.1304
8 (72.7%) 234 (91.8%)
3 (27.3%) 19 (7.5%)
0 (0.0%) 1 (0.4%)
0 (0.0%) 1 (0.4%)
0 (0.0%) 0 (0.0%)
0.1723
2 (11.1%) 16 (4.7%)
3 (16.7%) 81 (23.9%)
4 (22.2%) 117 (34.5%)
3 (16.7%) 73 (21.5%)
6 (33.3%) 52 (15.3%)
0.3157
3 (27.3%) 106 (41.7%)
4 (36.4%) 99 (39.0%)
4 (36.4%) 33 (13.0%)
0 (0.0%) 11 (4.3%)
0 (0.0%) 5 (2.0%)
Table 2
Characteristics of QFT-IT-negative patients at month 0 stratiﬁed by the absence or presence of positive conversion
With no positive conversion
during treatment (n = 11)
With positive conversion
during treatment (n = 8)
p-Value
Sex Male 11 (100.0%) 7 (87.5%) 0.4211
Female 0 (0.0%) 1 (12.5%)
Age at diagnosis, years 55.4 (37.4–67.0) 43.3 (30.8–49.0) 0.1167
Body mass index, kg/m2 16.7 (15.8–19.1) 15.9 (13.1–17.8) 0.3637
Smoking habit Smoker/ex-smoker 8 (72.7%) 6 (75.0%) 1.0000
Non-smoker 3 (27.3%) 2 (25.0%)
BCG vaccinationa No 1 (9.1%) 1 (12.5%) 1.0000
Yes 1 (9.1%) 0 (0.0%)
Unknown 9 (81.8%) 7 (87.5%)
Sputum smear Scanty 2 (18.2%) 0 (0.0%) 0.7611
+ 4 (36.3%) 4 (50.0%)
++ 3 (27.3%) 3 (37.5%)
+++ 2 (18.2%) 1 (12.5%)
HIV status Negative 9 (81.8%) 7 (87.5%) 1.0000
Positive 2 (18.2%) 1 (12.5%)
White blood cell count 109/l 8.6 (5.3–12.0) 9.9 (9.5–18.8) 0.2151
Lymphocyte count 109/l 1.4 (0.8–2.0) 2.1 (1.7–2.5) 0.1345
Drug resistance Isoniazid 1 (9.1%) 1 (12.5%) 1.0000
Rifampicin 1 (9.1%) 0 (0.0%) 1.0000
Streptomycin 2 (18.2%) 1 (12.5%) 1.0000
Ethambutol 1 (9.1%) 0 (0.0%) 1.0000
HLA-DRB1*07:01 allele number 0 6 (54.5%) 6 (75.0%) 0.1852
1 4 (36.4%) 0 (0.0%)
2 1 (9.1%) 2 (25.0%)
MTB strainsb Beijing 1 (11.7%) 2 (25.0%) 0.5335
EAI 6 (66.7%) 3 (37.5%)
Other 2 (22.2%) 3 (37.5%)
QFT-IT, QuantiFERON-TB in-tube; BCG, bacille Calmette–Gue´rin; MTB, Mycobacterium tuberculosis.
a Self-declaration.
b n = 9 and n = 8.
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months 2 or 7, in patients showing negative results at month
0 without positive conversion, and in 21 randomly selected
patients who showed a QFT-IT-positive result at month 0, and then
completed the treatment course.
Of the 27 immune analytes in the plasma supernatants, IL-1RA,
IL-2, IFN-g, and IP-10 showed differences in concentrations among
the groups, even after Bonferroni correction; these immunological
parameters were predominantly induced in the QFT-IT-positive
reference group, whereas their concentrations in QFT-IT-negative
subgroups were low (Figure 1). Although the induction levels of
these immune parameters gradually decreased during treatment
in the QFT-IT-positive group, signiﬁcant differences remained
between the QFT-IT-positive group and the continuously negative
group without positive conversion. In the transiently negative
group with positive conversion, levels of these immune param-
eters were restored to some extent during the course of treatment;
concentrations of IL-1RA and IL-2 in the transiently negative group
were signiﬁcantly higher than those in the continuously negative
group at month 7 (Figure 1). Concentrations of IL-10, known as a
regulatory cytokine, were not signiﬁcantly different between these
two subgroups; adiponectin concentrations did not show a
signiﬁcant difference either (data not shown).
4. Discussion
The QFT-IT test results of Vietnamese patients with culture-
conﬁrmed active pulmonary TB enrolled in a cross-sectional study
were recently reported,3 and factors that possibly lower the
sensitivity of this ELISA-based IGRA were identiﬁed: aging,
emaciation, HIV co-infection, and a particular HLA genotype,
DRB1*07:01.3 In the present study, the IGRA-negative TB patients
from the previous study underwent continued monitoring during
treatment, and treatment-dependent changes in immune status
were characterized by measuring the concentrations of cytokines
and chemokines in the plasma supernatants.IL-1RA, IL-2, and IP-10, as well as IFN-g, were more or less
inducible after TB antigen-speciﬁc stimulation (TBAg minus Nil) in
active pulmonary TB. The induction levels were signiﬁcantly lower
in the continuously IGRA-negative group than in the IGRA-positive
group, even after initiating treatment. This is possibly due to
immune regulatory mechanism(s), including impaired antigen
presentation through a particular HLA molecule or long-lasting
T-cell anergy,6,7 although immunoregulatory IL-10 levels relevant
to the regulatory T-cells were not different between these groups.
The difference in cytokine/chemokine induction was gradually
lost between the IGRA-positive group and the transiently IGRA-
negative group. The immune dynamics in the patients in whom the
immune response was restored may be consistent with those of an
early report, which showed the suppression of IFN-g production
from CD4+ T-cells in response to TB-speciﬁc peptides in patients
with severe pulmonary TB before treatment.2 However, the IFN-g
response was fully restored (>1 IU/ml) during the treatment
period in only three of the 19 patients (16%).
It has thus been demonstrated that IGRA-negative patients tend
to have continuously low immune responsiveness despite
successful treatment, measuring not only IFN-g but also other
immune molecules. These ﬁndings indicate that factors unaffected
by treatment are important when negative IGRA results are
interpreted in active TB.
IL-1RA is a natural antagonist of IL-1 produced by activated
monocyte/macrophages, and blocks the binding of IL-1a and IL-1b
to the type I IL-1 receptor, without exerting agonist activity. IL-1RA
is elevated in the blood of patients with inﬂammation, and IL-1RA
has been suggested as a marker for TB disease activity and
response to treatment.8 Increased levels of IL-1RA were found both
in the lung epithelial lining ﬂuid and in the blood from patients
with active pulmonary TB.9 IL-1 is not easily detected in the
circulation during human disease, and IL-1RA may be a better
maker than IL-1 as an indicator of ongoing inﬂammation.10
The restoration of IL-2 production in the IGRA-negative group
with positive conversion is consistent with previous reports:11,12
Figure 1. Immune analyte concentrations after TB antigen-speciﬁc stimulation at months 0, 2, and 7. Immune analyte concentrations (ng/ml) after TB antigen-speciﬁc
stimulation (TBAg minus Nil) were compared among IGRA-negative groups at month 0 with positive conversion at months 2 or 7 (NP) and without positive conversion (NN),
and the IGRA-positive reference group at month 0 (P). A signiﬁcant difference in IL-1RA, IL-2, IFN-g, and IL-2 concentrations was observed even after Bonferroni correction
(uncorrected p < 0.0005 by Kruskal–Wallis test). All pairs were further compared by Steel–Dwass method, and their signiﬁcant p-values are shown.
I. Matsushita et al. / International Journal of Infectious Diseases 40 (2015) 39–44 43in patients with normal TB immunity, it is known that antigen-
speciﬁc IFN-g-only-secreting effector T-cells are predominant
before treatment and dual IFN-g/IL-2-secreting or polyfunctional
T-cells with memory cell characteristics become predominant
after starting treatment.11,12 In the continuously IGRA-negative
group, effector memory T-cells might have failed to expand for
unknown reasons. Indeed, when the suspension array data
were analyzed, low IL-2 induction in QFT-IT was observed together
with the low IFN-g response in the patients without positive
conversion.
IP-10 is a chemokine expressed by antigen-presenting cells
in response to IFN-g, and IP-10-based tests are comparable with
the IGRA response13 before and during treatment.14 This studygroup has previously reported that circulating adiponectin may
be a marker for the severity of the disease,15 but this parameter
was not clearly associated with IGRA results in the present
study.
Changes in clinical phenotypes relevant to treatment failure,
such as chest radiographic lesions and smear-negative conversion,
were not associated with the IGRA results at month 0. In the
present study, the transiently IGRA-negative group with positive
conversion did not show any clinical backgrounds distinct from
those of the continuously IGRA-negative group without positive
conversion, presumably because disease severity is further
affected by the combination of other factors including patient
age, patient BMI, and the bacterial burden.
I. Matsushita et al. / International Journal of Infectious Diseases 40 (2015) 39–4444Furthermore, M. tuberculosis strains of non-Beijing EAI geno-
type were frequently observed in the IGRA-negative group in this
study. This may be partly confounded by the fact that non-Beijing
strains are often observed in elderly people in Hanoi.16 However,
conﬁrmation based on multivariable analysis was not performed
because of the small sample size.
The HLA-DRB1*07:01 allele, an endogenous genetic factor, has
previously been reported to be associated with QFT-IT false-
negative results or a low IFN-g response.3 This tendency was
shown throughout the treatment course in the present study,
although it did not reach statistical signiﬁcance, presumably due to
the relatively small sample size.
These ﬁndings will provide insights into factors affecting QFT-IT
false-negative results over a long term, although they may not be
extrapolated to those of another IGRA, the T-SPOT.TB. Neverthe-
less, a variety of factors that potentially suppress the IGRA
response should be investigated further and the test performance
of the IGRA should be improved in future studies.
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